Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomised, single-blind, placebo-controlled, phase 1 trial
Kevin FitzgeraldMaria Frank-KamenetskyAlnylam Pharmaceuticals, Cambridge, MA, USASvetlana Shulga‐MorskayaAlnylam Pharmaceuticals, Cambridge, MA, USAAbigail LiebowAlnylam Pharmaceuticals, Cambridge, MA, USABrian R. BettencourtAlnylam Pharmaceuticals, Cambridge, MA, USAJessica E. SutherlandAlnylam Pharmaceuticals, Cambridge, MA, USARenta HutabaratAlnylam Pharmaceuticals, Cambridge, MA, USAValerie A. ClausenAlnylam Pharmaceuticals, Cambridge, MA, USAVerena KarstenAlnylam Pharmaceuticals, Cambridge, MA, USAJeffrey CehelskyAlnylam Pharmaceuticals, Cambridge, MA, USASaraswathy V. NochurAlnylam Pharmaceuticals, Cambridge, MA, USAVictor KotelianskiAlnylam Pharmaceuticals, Cambridge, MA, USAJay D. HortonInternal Medicine and Molecular Genetics, University of Texas South Western, Dallas, TX, USATimothy MantQuintiles Drug Research Unit at Guy's Hospital, London, UKJoseph ChiesaCovance Clinical Research Unit, Leeds, UKJames M. RitterQuintiles Drug Research Unit at Guy's Hospital, London, UKMalathy MunisamyCovance Clinical Research Unit, Leeds, UKAkshay VaishnawAlnylam Pharmaceuticals, Cambridge, MA, USAJared GollobAlnylam Pharmaceuticals, Cambridge, MA, USAAmy SimonAlnylam Pharmaceuticals, Cambridge, MA, USA
2013en
ABI
Abstract
No abstract available.
Identifiers
Citations and references
Cited by 20 references